Trial reportNature communications2025
Acellular, bioresorbable, ultra-purified alginate gel implantation for intervertebral disc herniation: Phase 1/2, open-label, non-randomized clinical trials.
Trial report in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Ultrasound-responsive CPS piezoelectric hydrogel synergistically repairs annulus fibrosus defects through immune reprogramming and cell recruitment.Materials today. Bio · 2026Article
- Adapt, Mitigate, and Target: The Role of Oxidative Stress in Intervertebral Disc Homeostasis and Disc Degeneration.Neurospine · 2026Review
- Sculpting the Future of Bone: The Evolution of Absorbable Materials in Orthopedics.Advanced materials (Deerfield Beach, Fla.) · 2026Review
- Data Mining-Based Analysis of Acupoint Selection Patterns in Acupuncture Treatment for Lumbar Disc Herniation.Journal of pain research · 2026Review
- Mechanobiology of intervertebral disc degeneration: From pathological mechanisms to therapeutic approaches.Mechanobiology in medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Discectomy is the current surgical procedure for lumbar intervertebral disc (IVD) herniation. Discectomy was performed to remove the IVD material and relieve the pain inflicted by nerve root compression and axonotoxic effects, such as inflammatory cytokines in the IVD material; however, defects within the IVD caused by discectomy may impair tissue healing and predispose patients to subsequent IVD degeneration. Given that viable cells with the capacity for IVD regeneration are scarce, discectomy alone is not conducive to tissue repair. Here, we report the use of an acellular, bioresorbable, ultra-purified alginate (UPAL) gel implantation system to prevent IVD degeneration after discectomy and demonstrate its feasibility and safety in phase 1/2, open-label, non-randomized clinical trials conducted at a double center. This study comprised two parts: a prospective study on UPAL gel implantation after discectomy in patients with lumbar disc herniation, and a subsequent prospective study on patients who underwent discectomy without UPAL implantation as a control group. The control group was recruited separately. The primary outcomes of this study were the feasibility and safety of UPAL implantation, and the secondary outcomes included physical function scores, self-report questionnaires (SRQs) evaluating pain and health-related quality of life and magnetic resonance imaging (MRI)-based measures of IVD tissues. The UPAL gel implantation demonstrated 100% feasibility and safety (n = 40). The physical function scores improved significantly postoperatively in both groups, with the UPAL group demonstrating greater improvements over time compared to the control group. The SRQ scores were significantly higher in the UPAL group than in the control group from the early postoperative period to 12 weeks. MRI revealed that the disc degeneration score was significantly lower in IVDs with UPAL implantation than in those that underwent discectomy alone. The findings of this study suggest that the UPAL gel is a novel therapeutic strategy after discectomy in cases of lumbar IVD herniation. Trial number: UMIN000034227, UMIN000042282.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.